Sana expects to begin Phase 1/2 trial for SC451 in type 1 diabetes this year
Company anticipates initial clinical data for SG293 in non-Hodgkin lymphoma this year
Company expects cash runway to extend into mid-2027
Overview
Cell therapy developer's Q2 adjusted loss per share beat analyst expectations
Q2 adjusted net loss also beat analyst expectations
Company raised $93.3 mln in equity, cash runway expected into mid-2027
Result drivers
R&D spending - Increased research, laboratory, and clinical development costs for SC451 and SG293 programs drove higher Q2 R&D expenses
Non-cash expenses - Higher non-cash expenses from changes in estimated fair value of success payment liabilities and contingent consideration impacted results
Facility costs - General and administrative expenses rose due to increases in facility and other allocated costs
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
SANA•
